EXPEDITION
LIVE

Serial Number

98785584

Owner

EXPEDITION MEDICINES, INC.

Attorney

Christina M. Licursi

Filing Date

Oct 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

EXPEDITION Trademark

Serial Number: 98785584

EXPEDITION is a trademark filed by EXPEDITION MEDICINES, INC. on October 4, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

EXPEDITION MEDICINES, INC. (7 trademarks)

55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142

Entity Type: 03

Flagship Labs 94, Inc. (3 trademarks)

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

October 4, 2024

Registration Date

Not Registered

Published for Opposition

September 16, 2025

Goods & Services

Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; protein based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; pharmaceuticals for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; therapeutics, namely, therapeutic agents for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based and small molecule pharmaceuticals for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, or management of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based pharmaceuticals for the treatment, prevention, mitigation, or management of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders

Downloadable software for use in the pharmaceuticals and healthcare fields, namely, for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; downloadable software for providing life science analytics

Scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products; research services in the fields of genomic and transcriptomic analysis; genomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; research, development, and consultancy in the field of genomics; consultancy in the field of proteomics; medical research, namely, compiling data for research purposes in the field of genomics; Software as a service (SAAS) services featuring software using artificial intelligence for use in the fields of healthcare for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; software as a service (SAAS) services featuring software using artificial intelligence for use in the biotechnology field for discovering and designing biomolecules and chemical structures; software as a service (SAAS) services featuring software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; providing temporary use of on-line non downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; DNA analysis and sequencing services for scientific and research purposes; providing on-line non downloadable software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta genomics, meta-transcriptomics, and microbiomics; platform as a service (PaaS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, and meta-transcriptomics

Filing History

CORRECTED NOA E-MAILED
May 26, 2026 NOAC
DIVISIONAL PROCESSING COMPLETE
May 26, 2026 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 2, 2026 AITU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2025 EXRA
DIVISIONAL REQUEST RECEIVED
Dec 11, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Dec 11, 2025 ERTD
SOU EXTENSION 1 GRANTED
Dec 11, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 11, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 11, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 16, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 16, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 10, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 14, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 31, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 31, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 31, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 1, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 1, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 1, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 9, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 3, 2025 NWOS
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 5, 2025 ASGN
NEW APPLICATION ENTERED
Oct 4, 2024 NWAP